MAP Pharma files new drug application. U.S. jury finds Novartis not liable. Print
By Staff   
Thursday, 26 May 2011 19:40
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 26, 2011.

MAP Pharmaceuticals Inc., (NASDAQ:MAPP) has submitted a new drug application to the FDA for its experimental acute migraine drug.  Allergan Inc. (NYSE:AGN) had bought co-promotion rights to the drug Levadex, a potential treatment for migraine in January this year.  The development program evaluated Levadex in about 1000 patients and treated nearly 10,000 migraines in one year, the company said in a statement.  

The NDA submission is based on a development program for the drug and includes efficacy and safety data from the late-stage clinical trial, which proved the drug effective at two hours compared with patients on placebo.

Novartis Pharmaceuticals Corp (NYSE:NVS) was cleared by a U.S. federal jury that the bone drug made by the company was not to blame for the severe jaw deterioration developed by a Rhode Island man who died of cancer in 2005.

in a lawsuit filed in 2006, Karleen Hogan, the widow of Timothy Hogan, claimed Novartis had failed to properly warn her husband about the severe adverse effects caused by Zometa, a drug used to strengthen bones in cancer patients. She sought compensatory damages for her husband's suffering.

The suit is one of an estimated 600 filed against the unit of Novartis AG in recent years blaming the company for suppressing information about adverse effects linked to Zometa and Aredia, another bone-strengthening drug.

Also Thursday:

Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that John McManus, the company's Chief Executive Officer, will presenting at

ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) (OTCQB:APCSF) (the "Company" or "ALDA") has filed its patent application, "Antiseptic Compositions for the Treatment of Infections", with the US Patent and Trademark Office (Serial #12/933,358).

Altitude Organic Corporation (PINKSHEETS: ERBB), a leading national, publicly-traded medical marijuana company, announced today the National Cannabis Industry Association (NCIA) sponsored multiple Federal bills introduced in the House of Representatives today pertaining to marijuana legislation around the country

Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) ("Amylin" or "the Company") today announced that the United States District Court for the Southern District of California issued a temporary restraining order (TRO) against Eli Lilly and Company (NYSE:LLY) ("Lilly") relating to its litigation with respect to the Amylin / Lilly diabetes collaboration agreement.

Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTICD and MTA: CTIC) today announced that consistent with its previously announced pipeline strategy, CTI has identified a potential acquisition opportunity that is a phase II drug candidate being investigated in the field of cancer immunotherapy.

Connectyx Technologies Holdings Group, Inc. (PINKSHEETS: CTYX) ("Connectyx"), manufacturer and distributor of the MedFlash®, an innovative Personal Health and Wellness Management System (ePHM) for maintaining personal health records (PHR), announced today that the Company has completed three instructional Webinars for all 27 State Coalition Board members of the National Coalition of Eye Care IPA's (NCECIPA) as part of the rollout of MedFlash.

Cytori Therapeutics (NASDAQ: CYTX) has learned that the Japanese Ministry of Health, Labor and Welfare ("MHLW"), the Japanese health regulatory body, has approved Nagoya University's independent clinical study to assess the efficacy of adipose-derived stem and regenerative cells (ADRCs) in the treatment of stress urinary incontinence.

Life Technologies Corporation (NASDAQ:LIFE) today launched its LifeScope™ 2.0 Genomic Analysis Software, a significantly enhanced bioinformatics system for analyzing data from genomic sequencing instruments to study human disease such as cancer.

Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, will present on on June 2, 2011 at 1:00 PM EDT.

MAP Pharmaceuticals, Inc. (Nasdaq:MAPP) today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults.

Neurologix, Inc. (OTCBB: NRGX) announced the presentation today of efficacy results through one year of follow-up in patients treated as part of the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD).

PAREXEL International Corporation (NASDAQ:PRXL), a leading global biopharmaceutical services provider, today announced that it has been selected as one of two strategic partners by Pfizer Inc. to provide clinical development services.

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the Jefferies 2011 Global Healthcare Conference at the Grand Hyatt Hotel in New York City, June 6-9, 2011.

Verisante Technology, Inc. (TSX VENTURE:VRS) (OTCQX:VRSEF) (the "Company" or "Verisante") announced today that the Company will begin trading on the OTCQX International Tier as of the market opening on Thursday, May 26, 2011.

ViroPharma Incorporated (NASDAQ:VPHM) today announced the launch of the documentary Swell, a twenty-five minute film that allows families dealing with the rare genetic swelling disease, hereditary angioedema (HAE), to share the challenges and triumphs of living with a chronic disorder.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus